Publicaciones en colaboración con investigadores/as de Netherlands Cancer Institute (18)

2024

  1. EUSOMA quality indicators for non-metastatic breast cancer: An update

    European Journal of Cancer, Vol. 198

  2. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 9, pp. 2706-2732

  3. Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines

    European Journal of Nuclear Medicine and Molecular Imaging

  4. Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines

    Breast, Vol. 78

2023

  1. EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy

    European Journal of Cancer, Vol. 181, pp. 79-91

  2. The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus

    eClinicalMedicine, Vol. 61

  3. Uncertainties and controversies in axillary management of patients with breast cancer

    Cancer Treatment Reviews, Vol. 117

2022

  1. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy

    Breast, Vol. 63, pp. 123-139

2021

  1. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 476-488

  2. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox

    The Lancet Oncology, Vol. 22, Núm. 1, pp. e18-e28

  3. The ESSO core curriculum committee update on surgical oncology

    European Journal of Surgical Oncology, Vol. 47, Núm. 11, pp. e1-e30

2020

  1. Missed opportunities and challenges for surgical breast cancer research in the era of personalized cancer treatment

    European Journal of Surgical Oncology

  2. Standard anthracycline based versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT phase III trial

    Journal of Clinical Oncology, Vol. 38, Núm. 11, pp. 1186-1197

2018

  1. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    EMBO Molecular Medicine, Vol. 10, Núm. 12

  2. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1203-1210

2016

  1. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer

    New England Journal of Medicine, Vol. 375, Núm. 8, pp. 717-729

2011

  1. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase

    European Journal of Cancer, Vol. 47, Núm. 18, pp. 2742-2749

2010

  1. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: first results of the pilot phase

    EJC SUPPLEMENTS